Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection

21 Jun 2024

Abstract excerpt

Epstein-Barr virus (EBV) infects more than 95% of adults worldwide and is closely associated with various malignancies. Considering the complex life cycle of EBV, developing vaccines targeting key entry glycoproteins to elicit robust and durable adaptive immune responses may provide better protection. EBV gHgL-, gB- and gp42-specific antibodies in healthy EBV carriers contributed to sera neutralizing abilities in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to Herpesvirus Infections and Treatments
Share to Virology and Viral Diseases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38906867
DOI: 10.1038/s41467-024-49546-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infectionPMID 38906867Read ↗

Progress in Prophylactic and Therapeutic EBV Vaccine Development Based on Molecular Characteristics of EBV Target AntigensSemantic proximity Read ↗

Contriving multiepitope subunit vaccine by exploiting structural and nonstructural viral proteins to prevent Epstein–Barr virus‐associated malignancySemantic proximity Read ↗

Non-overlapping epitopes on the gHgL-gp42 complex for the rational design of a triple-antibody cocktail against EBV infectionSemantic proximity Read ↗

Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in miceSemantic proximity Read ↗

A Virus-Like Particle-Based Epstein-Barr Virus VaccineSemantic proximity Read ↗

A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infectionSemantic proximity Read ↗

An insect cell-derived extracellular vesicle-based gB vaccine elicits robust adaptive immune responses against Epstein-Barr virusSemantic proximity Read ↗

Eliciting B cell immunity against infectious diseases using nanovaccines.Semantic proximity Read ↗

A Promising Liposomal Vaccine Candidate Against Epstein–Barr Virus: An In Vitro EvaluationSemantic proximity Read ↗

Identification of a Novel Neutralizing and Two Non-Neutralizing Epitopes on Epstein-Barr Virus gp350 ProteinSemantic proximity Read ↗

Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal CarcinomaSemantic proximity Read ↗

Human Cytomegalovirus Vaccine Based on the Envelope gH/gL Pentamer ComplexSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.